Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

(2016) Adrian S. Ray et al.   ANTIVIRAL RESEARCH

Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results

(2016) Celia Oldenbuettel et al.   ANTIVIRAL THERAPY

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

(2016) Erik De Clercq   BIOCHEMICAL PHARMACOLOGY

Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia

(2016) Pornpimol Thamrongwonglert et al.   HIV CLINICAL TRIALS

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women

(2016) Anna H. Tran et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

(2016) Anton Pozniak et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2016) David Wohl et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

(2016) Anthony Mills et al.   LANCET INFECTIOUS DISEASES

Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents

(2016) Johan Lombaard et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study

(2016) Phairote Teeranaipong et al.   PLoS One

Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection*

(2016) Camille Bernaud et al.   Infectious Diseases

HIV Prevention 2020: a framework for delivery and a call for action

(2016) Karl L Dehne et al.   Lancet HIV

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

(2016) Jean-Guy Baril et al.   PLoS One

Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors

(2015) Gabriel Birkus et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

(2015) R Verloes et al.   HIV MEDICINE

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) JD Baxter et al.   HIV MEDICINE

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

(2015) Kosh Agarwal et al.   JOURNAL OF HEPATOLOGY

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

(2015) Paul E Sax et al.   LANCET

Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy

(2015) Salim S. Abdool Karim   NEW ENGLAND JOURNAL OF MEDICINE

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Formulation and pharmacology of long-acting rilpivirine

(2015) Peter E. Williams et al.   Current Opinion in HIV and AIDS

Current state and limitations of daily oral therapy for treatment

(2015) Daniel A. Solomon et al.   Current Opinion in HIV and AIDS

Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy

(2014) Margaret T. May et al.   AIDS

Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

(2014) Georg Behrens et al.   AIDS PATIENT CARE AND STDS

Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity

(2014) Rujuta A Bam et al.   ANTIVIRAL THERAPY

Effectiveness of efavirenz compared with ritonavir-boosted protease inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml

(2014) Arkaitz Imaz et al.   ANTIVIRAL THERAPY

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

(2014) Paul E. Sax et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

(2014) B. Mora-Peris et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Has the time come to abandon efavirenz for first-line antiretroviral therapy?

(2014) F. Raffi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults

(2014) M. Markowitz et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Single-Pill Combination Regimens for Treatment of HIV-1 Infection

(2014) Monica Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neurological and psychiatric tolerability of rilpivirine (TMC278)vs.efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks

(2013) AM Mills et al.   HIV MEDICINE

Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults

(2013) Peter J. Ruane et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

(2009) Anton L Pozniak et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine

(2009) Tomas Cihlar et al.   ANTIVIRAL RESEARCH

Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor

(2009) Lucy Garvey et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets

(2009) C. S. Adamson et al.   MOLECULAR INTERVENTIONS